⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13731096 | 0.97 | — | — | |
| SCHEMBL1681003 | 0.91 | PRMT6 (0.52) | — | |
| Methoxyamine SCHEMBL9232343 | 0.89 | PRMT6 (0.45) | — | |
| SCHEMBL1362788 | 0.80 | — | — | |
| SCHEMBL23665620 | 0.78 | PRMT6 (0.58) | — | |
| SCHEMBL10017405 | 0.78 | PRMT6 (0.65) | — | |
| SCHEMBL19438869 | 0.77 | PRMT6 (0.47) | — | |
| SCHEMBL96145 | 0.76 | — | — | |
| SCHEMBL8105246 | 0.75 | PRMT6 (0.45) | — | |
| SCHEMBL1523312 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | claimed |
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | FAES FARMA, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4263547-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004072070-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5939398-A | ANTIATHEROSCLEROSIS AGENTS | PFIZER INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5051429-A | For treatment of autoimmune diseases such as arthritis, lupus, antiinflammatory agents, multiple sclerosis, diabetes and viral diseases | WARNER-LAMBERT CO. (US) | 1991-09-24 | — | — | US | disclosed |
| US-4952693-A | TREATING AUTOIMMUNE DISEASES | WARNER-LAMBERT COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | disclosed |